Verona Pharma
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 2005-01-01
- Employees
- 79
- Market Cap
- -
- Website
- http://www.veronapharma.com
- Introduction
Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. It focuses on developing inhaled ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.
Clinical Trials
46
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (41 trials with phase data)• Click on a phase to view related trials
A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Ensifentrine 1.5 mgDrug: Ensifentrine 3 mg (marketed formulation)Drug: Glycopyrrolate 42.5 mcg
- First Posted Date
- 2025-08-20
- Last Posted Date
- 2025-10-03
- Lead Sponsor
- Verona Pharma plc
- Target Recruit Count
- 30
- Registration Number
- NCT07132983
- Locations
- 🇺🇸
Clinical Research of West Florida Inc - Clearwater, Clearwater, Florida, United States
🇺🇸Clinical Research of West Florida Inc - Tampa, Tampa, Florida, United States
🇺🇸Midwest Chest Consultants PC, Saint Charles, Missouri, United States
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2025-06-11
- Last Posted Date
- 2025-09-22
- Lead Sponsor
- Verona Pharma plc
- Target Recruit Count
- 480
- Registration Number
- NCT07016412
- Locations
- 🇺🇸
SEC Clinical Research, LLC, Dothan, Alabama, United States
🇺🇸Elite Clinical Studies, LLC, Phoenix, Arizona, United States
🇺🇸Downtown LA Research Center Inc - ClinEdge, Los Angeles, California, United States
A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
- Conditions
- Non-cystic Fibrosis Bronchiectasis
- Interventions
- Drug: Nebulized Placebo Solution
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2025-09-23
- Lead Sponsor
- Verona Pharma plc
- Target Recruit Count
- 180
- Registration Number
- NCT06559150
- Locations
- 🇺🇸
Kirklin Clinic of UAB Hospital, Birmingham, Alabama, United States
🇺🇸So Cal Institute for Respiratory Diseases, Inc., Los Angeles, California, United States
🇺🇸University of California Davis Medical Center, Sacramento, California, United States
A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Verona Pharma plc
- Target Recruit Count
- 46
- Registration Number
- NCT06545500
- Locations
- 🇺🇸
Clinical Research of West Florida Inc - Clearwater, Clearwater, Florida, United States
🇺🇸Clinical Research of West Florida Inc - Tampa, Tampa, Florida, United States
🇺🇸Midwest Chest Consultants PC, Saint Charles, Missouri, United States
Effect of Ensifentrine Treatment on CAT Score
- Conditions
- COPD
- Interventions
- Drug: Ensifentrine 3 mg twice daily
- First Posted Date
- 2024-06-14
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Verona Pharma plc
- Target Recruit Count
- 20
- Registration Number
- NCT06460493
- Locations
- 🇺🇸
Midwest Chest Consultants, Saint Charles, Missouri, United States
- Prev
- 1
- 2
- 3
- 4
- Next